A Study of S-892216 in Participants With COVID-19

Summary

The primary objective of this study is to investigate the antiviral effect of S-892216 in participants with coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Timeline

Start

2025-06-06

Primary completion

2025-09-22

Completion

2025-09-22

Drugs

Indications